Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/Phase 2a Safety and Tolerability Study of Intracerebral Transplantation of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS) and Early Evaluation of Potentially Useful Efficacy Parameters

NCT04631406 is registered in ClinicalTrials.gov with Clarion Cells, Inc. as lead sponsor.

NCT NCT04631406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04631406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/Phase 2a Safety and Tolerability Study of Intracerebral Transplantation of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS) and Early Evaluation of Potentially Useful Efficacy Parameters
Lead sponsor
Clarion Cells, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 4, 2021
Completion date
August 31, 2029
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke